- Tytuł:
- Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
- Autorzy:
- Źródło:
- Lancet Oncology. May2022, Vol. 23 Issue 5, p636-649. 14p.
Czasopismo naukowe